Annals of Surgical Oncology

, Volume 25, Issue 5, pp 1418–1424 | Cite as

Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database

  • Katherine D. Gray
  • Maureen D. Moore
  • Suraj Panjwani
  • Adham Elmously
  • Cheguevara Afaneh
  • Thomas J. FaheyIII
  • Rasa Zarnegar
Endocrine Tumors

Abstract

Background

Neuroendocrine tumors (NETs) of the esophagus and stomach are rare neoplasms with variable behavior. We aim to describe their epidemiology and response to treatment.

Methods

NETs of the stomach and the esophagus were selected from the National Cancer Database (2004–2013) and classified by location. Survival analyses were performed with respect to tumor characteristics and treatment variables.

Results

NETs of the stomach (n = 2700; 92.8%) and esophagus (n = 210, 7.2%) were identified. Gastric cardia NETs had demographics and behavior similar to esophageal tumors and were associated with worse overall survival than NETs of the noncardia stomach independent of grade (p < 0.001). Poorly differentiated histology [hazard ratio (HR) 4.14, 95% confidence interval (CI) 2.26–7.57; p < 0.001] and distant metastases (HR 3.28, 95% CI 1.94–5.56; p < 0.001) were the greatest independent predictors of survival. For patients with poorly differentiated NETs, surgery was the only treatment to have benefit on overall survival (HR 0.38, 95% CI 0.27–0.54; p < 0.001) regardless of extent of disease. There was no additional benefit to adjuvant chemotherapy or radiation in patients undergoing resection (p = 0.39), even for patients with lymph node metastases (surgery alone versus surgery plus adjuvant therapy, p = 0.46), distant metastases (p = 0.19), or positive margins (p = 0.33).

Conclusions

Esophageal and gastric cardia NETs have worse survival than those of the noncardia stomach. Surgery offers the only survival benefit for poorly differentiated tumors, with no additional survival advantage to adjuvant chemotherapy or radiation.

Notes

Funding

This study was internally funded.

Disclosure

The authors have no disclosures.

References

  1. 1.
    Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1):1–16.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994–1006.CrossRefPubMedGoogle Scholar
  3. 3.
    Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;24(9):1305–1320.  https://doi.org/10.1111/j.1365-2036.2006.03130.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Borch K, Ahrén B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tustumi F, Takeda FR, Uema RH, Pereira GLS, Sallum RAA, Cecconello I. Primary neuroendocrine neoplasm of the esophagus–Report of 14 cases from a single institute and review of the literature. Arq Gastroenterol. 2017;54(1):4–10.  https://doi.org/10.1590/s0004-2803.2017v54n1-01.CrossRefPubMedGoogle Scholar
  6. 6.
    Deng H-Y, Ni P-Z, Wang Y-C, Wang W-P, Chen L-Q. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8(6):1250–1256.  https://doi.org/10.21037/jtd.2016.04.21.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Harmse JL, Carey FA, Baird AR, et al. Merkel cells in the human oesophagus. J Pathol. 1999;189(2):176–179. https://doi.org/10.1002/(SICI)1096-9896(199910)189:2<176::AID-PATH416>3.0.CO;2-U.Google Scholar
  8. 8.
    Egashira A, Morita M, Kumagai R, et al. Neuroendocrine carcinoma of the esophagus: clinicopathological and immunohistochemical features of 14 cases. PLoS ONE. 2017;12(3):e0173501.  https://doi.org/10.1371/journal.pone.0173501.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.  https://doi.org/10.1200/jco.2007.15.4377.CrossRefPubMedGoogle Scholar
  10. 10.
    Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351–1355.  https://doi.org/10.1038/sj.bjc.6690325.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991. Available at: http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19910715)68:2%3C227:AID-CNCR2820680202%3E3.0.CO;2-I/abstract.
  12. 12.
    Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.CrossRefPubMedGoogle Scholar
  13. 13.
    Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–1470.  https://doi.org/10.1016/j.ejso.2016.08.004.CrossRefPubMedGoogle Scholar
  14. 14.
    Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160.  https://doi.org/10.1093/annonc/mds276.CrossRefPubMedGoogle Scholar
  15. 15.
    Huang Q, Wu H, Nie L, et al. Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol. 2013;37(4):467–483.  https://doi.org/10.1097/pas.0b013e31826d2639.CrossRefPubMedGoogle Scholar
  16. 16.
    Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan–Kettering experience. Ann Oncol. 2008;19(3):533–537.  https://doi.org/10.1093/annonc/mdm476.CrossRefPubMedGoogle Scholar
  17. 17.
    Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800.  https://doi.org/10.1097/mpa.0b013e3181ebb56f.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751–757.  https://doi.org/10.1530/erc-12-0002.CrossRefPubMedGoogle Scholar
  19. 19.
    Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986–2991.  https://doi.org/10.1158/1078-0432.ccr-06-2053.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Katherine D. Gray
    • 1
  • Maureen D. Moore
    • 1
  • Suraj Panjwani
    • 1
  • Adham Elmously
    • 1
  • Cheguevara Afaneh
    • 1
  • Thomas J. FaheyIII
    • 1
  • Rasa Zarnegar
    • 1
  1. 1.Department of SurgeryNew York Presbyterian Hospital—Weill Cornell MedicineNew YorkUSA

Personalised recommendations